A Combined Epigenetic Therapy Equals the Efficacy of Conventional Chemotherapy in Refractory Advanced Non–Small Cell Lung Cancer
Mené sur 19 patients atteints d'un cancer du poumon non à petites cellules métastatique et récidivant, cet essai de phase I/II évalue la combinaison de deux traitements de nature épigénétique, l'azacitidine et l'entinostat
A new study by Juergens and colleagues provides the first successful example of a combined epigenetic therapy capable of achieving results similar to those of conventional chemotherapy in refractory metastatic non–small cell lung cancer. Furthermore, the authors describe interesting blood-based DNA methylation biomarkers that may be useful in predicting clinical response. Cancer Discovery; 1(7); OF1–OF3. ©2011 AACR.
Cancer Discovery , commentaire, 2011